[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646574":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":33,"eligibilityCriteria":34,"healthyVolunteers":29,"sex":35,"minAge":36,"maxAge":10,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":44,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Early Treatment Group",null,"Adult patients with moderate to severe HS, having up to 1 active tunnel (draining or non-draining) or up to 4 inflammatory lesions (abscess\u002Fnodules) at date of first secukinumab administration for HS treatment.",{"label":13,"type":10,"description":14,"interventionNames":10},"Late Treatment Group","Adult patients with moderate to severe HS, having \\>1 active tunnel or \\>4 inflammatory lesions, at date of first secukinumab administration for HS treatment.",[16],{"name":17,"affiliation":17,"role":18},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[20,24],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":17,"role":21,"phone":10,"phoneExt":10,"email":10},{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100646574","a-study-of-early-secukinumab-treatment-in-moderate-to-severe-hidradenitis-suppurativa-patients-100646574",false,"NCT07690319","A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients","Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients: Early Action Reduces Long-term Yield in Hidradenitis Suppurativa (EARLY HS 2)","EARLY-HS 2","Inclusion criteria:\n\n* Patients with a documented diagnosis of HS (e.g., International Classification of Diseases, 10th Revision \\[ICD-10\\] code L73.2);\n* Age ≥18 years at index date;\n* Moderate-to-severe HS as per label;\n* Initiation of secukinumab treatment on or after the first HS diagnosis date;\n* And at least one follow-up assessment at 6 or 12 months after index date.\n\nExclusion criteria:\n\n* Patients who had major HS-related surgery (Skin-tissue-sparing Excision with Electrosurgical Peeling \\[STEEP\\] or wide excision) in the 12 months prior to index date;\n* Patients participating in interventional clinical trials at index date.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":38,"type":39},186,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.",[43],"Hidradenitis Suppurativa",[43,45,46,47],"Secukinumab","Early treatment","Real-world evidence","NOT_YET_RECRUITING","2026-07-02",{"date":51,"type":52},"2026-07-08","ACTUAL",{"date":54,"type":39},"2026-10-15",{"date":56,"type":39},"2027-03-15",{"name":17,"class":6}]